PINTER, Elena
 Distribuzione geografica
Continente #
NA - Nord America 1.304
EU - Europa 483
AS - Asia 229
SA - Sud America 7
AF - Africa 3
OC - Oceania 1
Totale 2.027
Nazione #
US - Stati Uniti d'America 1.294
UA - Ucraina 151
IT - Italia 98
SE - Svezia 96
SG - Singapore 88
IN - India 87
FI - Finlandia 37
CN - Cina 25
GB - Regno Unito 23
DE - Germania 21
BG - Bulgaria 18
BE - Belgio 13
JP - Giappone 13
CA - Canada 9
FR - Francia 6
IE - Irlanda 5
KR - Corea 5
SI - Slovenia 5
ID - Indonesia 4
CL - Cile 3
IR - Iran 3
NL - Olanda 3
AR - Argentina 2
LV - Lettonia 2
RO - Romania 2
AU - Australia 1
AZ - Azerbaigian 1
BJ - Benin 1
BO - Bolivia 1
BR - Brasile 1
EG - Egitto 1
HR - Croazia 1
LT - Lituania 1
MX - Messico 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
TG - Togo 1
TR - Turchia 1
VN - Vietnam 1
Totale 2.027
Città #
Woodbridge 187
Chandler 127
Fairfield 121
Ann Arbor 95
Houston 89
Ashburn 72
Singapore 66
Jacksonville 60
Seattle 56
Princeton 54
Wilmington 47
Cambridge 46
Plano 37
Rome 34
San Diego 18
Sofia 18
Santa Clara 16
Beijing 13
Boston 13
Milan 13
Brussels 12
Lawrence 12
Millbury 12
Boardman 10
Dearborn 10
Florence 8
Andover 7
Los Angeles 7
Norwalk 7
Solbiate Olona 7
Auburn Hills 6
Falls Church 6
Dublin 5
Helsinki 5
Nova Gorica 5
Jakarta 4
Kyoto 4
Mannheim 4
Ottawa 4
San Mateo 4
San Paolo di Civitate 4
Toronto 4
Amsterdam 3
Bologna 3
Bremen 3
Bühl 3
Dallas 3
Falkenstein 3
Fremont 3
Jeonju 3
Mashhad 3
Shinchiba 3
Ahmedabad 2
Aversa 2
Des Moines 2
Edinburgh 2
Federal 2
Kobe 2
Laurel 2
Munich 2
Nanjing 2
New York 2
Phoenix 2
Riga 2
Sarno 2
Tovo San Giacomo 2
Azzano Decimo 1
Baku 1
Bend 1
Bengaluru 1
Blyth 1
Cairo 1
Castel di Sangro 1
Chicago 1
Cochabamba 1
Fasano 1
Frankfurt am Main 1
Gwangju 1
Hanoi 1
Honjocho 1
Hounslow 1
Indiana 1
Istanbul 1
Jeddah 1
Leuven 1
Lomé 1
Maedacho 1
Manchester 1
Melbourne 1
Mexico City 1
Montreal 1
Montrose 1
Naples 1
Nashville 1
Newcastle upon Tyne 1
Odesa 1
Philadelphia 1
Piacenza 1
Pieve di Soligo 1
Ponte San Pietro 1
Totale 1.421
Nome #
Sensitization to Gibberellin-regulated protein (Peamaclein) among Italian cypress pollen-sensitized patients 146
Amniocentesis and chorionic villus sampling in HIV-infected pregnant women: a multicentre case series 96
Pregnancy outcomes and cytomegalovirus DNAaemia in HIV-infected pregnant women with CMV 87
Acquired cow's milk sensitization after liver transplant in an adult: "clinical implications" and future strategies 80
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART 79
Leptin levels in HIV-positive patients treated with HAART 73
Human infection with Cryptosporidium felis: Case report and literature review 68
Good prenatal detection rate of major birth defects in HIV-infected pregnant women in Italy 67
Functional bone marrow analysis in HIV-1+ patients pre- and post-HAART 66
SERUM EOSINOPHIL CATIONIC PROTEIN (ECP) IN HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION 65
Rate, correlates and outcomes of repeat pregnancy in HIV-infected women 61
LACK OF EVIDENCE FOR A SUPERANTIGEN IN LYMPHOCYTES FROM HIV-DISCORDANT MONOZYGOTIC TWINS 60
Acute cystitis by Ureaplasma urealyticum in a patients with Acquired Immunodeficiency Syndrome. 59
USE OF HEMATOPOIETIC GROWTH FACTORS (RECOMBINANT HUMAN ERYTHROPOIETIN AND GRANULOCYTE COLONY-STIMULATING FACTOR) IN HIV-1 INFECTIONS 58
Correlation between HIV-induced serologic findings and retinal lesions in patients with AIDS 57
Lymphocyte subsets and functional changes in HIV-1 infected patient during HAART. 56
Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. 55
Occurrence of Pneumocystis carinii pneumonia in HIV-1-infected patients responding to highly active antiretroviral therapy: is prophylaxis discontinuation a safe tool? 51
Long-term evaluation of T cell subsets and T cell function after highly active antiretroviral therapy in advanced stage of HIV-1 disease 50
Valore diagnostico e prognostico del coinvolgimento del sistema nervoso in pazienti con infezione da HIV-1. 46
Esperienze cliniche, virologiche ed immunologiche con Indinavir per uso compassionevole: 80settimane di follow-up in due centri italiani (Milano e Roma). 45
Stage related decrease of memory and naive cells in HIV disease. 44
Preliminary results of a clinical study on amprenavir for patients on multiple treatments 43
IMMUNOLOGICAL, CLINICAL AND EPIDEMIOLOGIC ASPECTS OF AN HIV-1 POSITIVE-DRUG ABUSER COHORT 41
SILENT HIV-INFECTION 39
Manifestazioni allergiche in corso di malattia da HIV. 38
HYPER-IGE IN AIDS PATIENTS 38
Sottopopolazioni CD4+ nella patologia da HIV. 37
IMMUNOLOGICAL ASPECTS OF HYPERIMMUNOGLOBULINEMIA E-LIKE SYNDROME IN PATIENTS WITH AIDS 37
Hyper-IgE syndrome induced by HIV infection. 35
Systemic allergic reactions induced by labile plant-food allergens. Seeking potential cofactors. A multicenter study 34
Uso terapeutico degli aerosol nelle malattie allergiche e nella malattia da HIV. 33
HIV GENOMIC SEQUENCES IN SERONEGATIVE INDIVIDUALS AT HIGH-RISK FOR INFECTION 33
Spectrotype of anti-gp120 antibodies remains stable during the course of HIV disease. 32
Silent HIV Infection. 31
Type 1 and type 2 cytokine profile in AIDS-Kaposi's sarcoma patients after highly active antiretroviral therapy 30
La malattia da HIV-1: implicazioni epidemiologiche, evoluzione clinica ed approccio terapeutico. 29
Morphological and functional recovery of bone marrow in patients with HIV-1 disease undergoing HAART 27
TH2-TYPE CYTOKINE PRODUCTION, EOSINOPHILS AND SERUM IGE LEVELS IN HIV-INFECTION 25
Mollusk allergy in shrimp-allergic patients: Still a complex diagnosis. An Italian real-life cross-sectional multicenter study 17
Peanut allergy in Italy: A unique Italian perspective 2
Totale 2.070
Categoria #
all - tutte 5.874
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.874


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020272 0 0 0 0 27 56 45 48 33 38 11 14
2020/2021201 22 29 31 16 2 20 0 19 12 31 15 4
2021/2022311 1 24 28 17 56 6 4 44 15 26 29 61
2022/2023418 77 31 26 53 70 54 7 26 42 1 28 3
2023/2024211 13 39 11 14 24 18 4 13 2 30 25 18
2024/2025129 23 9 39 18 40 0 0 0 0 0 0 0
Totale 2.070